| Composition : Atorvastatin 10mg & 20mg tablets. |
| Clinical Pharmacology |
Act as inhibitor of HMG-CoA reductase. |
| Pharmacokinetics & Metabolism |
Absorption: Atorvastatin (Orvas) is rapidly absorbed after oral administration. Extent of absorption increases in proportion to Atorvastatin (Orvas) dose. |
| Distribution |
Mean volume of distribution of Atorvastatin (Orvas) is approximately 381 liters bound to plasma proteins. A blood / plasma ratio of approximately 0.25 indicates poor drug per on observation in rats.
Metabolism: Atorvastatin (Orvas) is extensively metabolized to ortho-and para oxidation products.
Erection: Atorvastatin (Orvas) and its metabolites are eliminated primarily in bile; however, the drug does not appear to undergo enterohepatic recirculation. |
| Special Populations |
Aged: Plasma concentrations of Atorvastatin (Orvas) are higher in elderly subjects (age 365 years) than in young adults.
Pediatric: Pharmacokinetic data in the pediatric population are not available.
Gender: There is no clinically significant difference in LDL-C reduction with Atorvastatin (Orvas).
Renal Efficiency: Renal disease has no influence on the plasma concentrations or LDL-C reduction thus, dose adjustment in patients with renal dysfunction is not necessary.
Hepatic Insufficiency: In patients with chronic alcoholic liver disease, plasma concentrations markedly increased. Cmax and AUC are each 4-fold greater in patients with Childs-Pugh A disease approximately 16-fold and 11-fold increased, respectively, in patients with Childs-Pugh B disease. |
| Indications |
Familial hypercholesterolemia
Hypercholesterolemia
Coronary Artery disease
Dyslipidemia
Diabetes mellitus |
| Sales Pack |
Orvas - 10 : Pack of 50 tabs/ box (5 x 10)
Orvas - 20 : Pack of 30 tabs/ box (3 x 10) |
